Deferiprone

Deferiprone
Clinical data
Trade names	Ferriprox
AHFS/Drugs.com	Monograph
MedlinePlus	a612016
License data	US DailyMed: Deferiprone;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	V03AC02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only) / P; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Metabolism	Glucuronidation
Elimination half-life	2 to 3 hours
Excretion	Kidney (75 to 90% in 24 hours)
Identifiers
	IUPAC name 3-hydroxy-1,2-dimethylpyridin-4(1H)-one;
CAS Number	30652-11-0 ;
PubChem CID	2972;
IUPHAR/BPS	7456;
DrugBank	DB08826 ;
ChemSpider	2866 ;
UNII	2BTY8KH53L;
KEGG	D07416 ;
ChEBI	CHEBI:68554 ;
ChEMBL	ChEMBL70927 ;
CompTox Dashboard (EPA)	DTXSID6040666 ;
ECHA InfoCard	100.157.470
Chemical and physical data
Formula	C7H9NO2
Molar mass	139.154 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C\1C(\O)=C(/N(/C=C/1)C)C;
	InChI InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3 ; Key:TZXKOCQBRNJULO-UHFFFAOYSA-N ;
	(what is this?) (verify)

Deferiprone, sold under the brand name Ferriprox among others, is a medication that chelates iron and is used to treat iron overload in thalassaemia major. It was first approved and indicated for use in treating thalassaemia major in 1994 and had been licensed for use in the European Union for many years while awaiting approval in Canada and in the United States. On 14 October 2011, it was approved for use in the US under the FDA's accelerated approval program.

The most common side effects include red-brown urine (showing that iron is being removed through the urine), nausea (feeling sick), abdominal pain (stomach ache) and vomiting. Less common but more serious side effects are agranulocytosis (very low levels of granulocytes, a type of white blood cell) and neutropenia (low levels of neutrophils, a type of white blood cell that fights infections).